Noticias de SVRA_US

Noticias del mercado

Últimas noticias sobre SVRA_US — 201 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SVRA_US ✕ 201 resultados
10/04/2026 SVRA_US — Stock Titan
Savara Inc. (NASDAQ: SVRA) proxy: MOLBREEVI FDA date, equity and vote items
10/04/2026 SVRA_US — MyChesCo
Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K.
10/04/2026 SVRA_US — laocai.gov.vn
Is Savara (SVRA) Stock Trending Down | Price at $5.61, Down 4.51% - Trader Community Insights
09/04/2026 SVRA_US — simplywall.st ES ← EN
Savara (SVRA) ha subido un 6,5% después de que se concedieran revisiones aceleradas en varias regiones para la terapia MOLBREEVI
08/04/2026 SVRA_US — haiphong.gov.vn
How does currency impact Savara (SVRA) Stock | Price at $5.93, Up 2.68% - Social Momentum Signals
08/04/2026 SVRA_US — Xã Châu Thành ES ← EN
¿Cómo afecta la moneda a las acciones de Savara (SVRA) | Precio a $ 5,93, aumento del 2,68 % - Señales de impulso social
08/04/2026 SVRA_US — news.google.com
How does currency impact Savara (SVRA) Stock | Price at $5.93, Up 2.68% - High Beta Stocks
07/04/2026 SVRA_US — ChartMill
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
07/04/2026 SVRA_US — Yahoo Finance
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
07/04/2026 SVRA_US — Business Wire
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
31/03/2026 SVRA_US — Investing.com
Citizens reiterates Savara stock rating on regulatory progress
30/03/2026 SVRA_US — Yahoo Finance
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
30/03/2026 SVRA_US — Investing.com
Jefferies sees Savara stock approval odds at 90% for rare lung drug
30/03/2026 SVRA_US — Investing.com
EMA validates Savara’s MOLBREEVI application for autoimmune PAP
30/03/2026 SVRA_US — Investing.com
Jefferies reiterates Savara stock Buy rating on approval confidence
30/03/2026 SVRA_US — Bitget ES ← EN
Savara Inc anunció que su Solicitud de Autorización de Comercialización (MAA) para Molbreevi*, un tratamiento para la Proteinosis Alveolar Pulmonar Autoinmune (PAP Autoinmune), ha sido validada formalmente por la Agencia Europea de Medicamentos (EMA).

Savara Inc anunció que su Solicitud de Autorización de Comercialización (MAA) para Molbreevi*, un tratamiento para la Proteinosis Alveolar Pulmonar Autoinmune (PAP Autoinmune), ha sido validada formalmente por la Agencia…

30/03/2026 SVRA_US — Business Wire
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
30/03/2026 SVRA_US — The Chronicle-Journal
User
27/03/2026 SVRA_US — MarketBeat ES ← EN
Savara Inc. (NASDAQ:SVRA) recibe la calificación de consenso de "compra moderada" de las casas de bolsa
23/03/2026 SVRA_US — MyChesCo
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval

Página 10 de 11

keyboard_arrow_up